LadRx Corp (LADXD)

[seanknowsall]

(CYTR) GETS POSITIVE ORPHAN DRUG REVIEW. RODMAN & RENSHAW HAS $3 TARGET Analyst Simos Simeonidis says next step in the process is final approval by EU commission for batetinib as a treatment for chronic myeloid leukemia (CML). If approved in CML, CYTR will get 10 yrs of market exclusivity in EU, along with possible exemptions for reduction in regulatory fees, eligibility for protocol assistance. Says CYTR is gearing up for a crucial year, as it completes transformation from neurology and RNAi co., to oncology co. Notes there are 6 ph. II oncology trials starting in 2010. Reiterates mkt outperform, $3 target./Trombino|US;CYTR|57408|US|85095